Flagship Pioneering’s Post

NEW: Flagship Pioneering, the venture capital fund that launched Moderna, is planning to create a spree of new biotechs harnessing generative artificial intelligence to power drug discovery after securing $3.6bn in funding from its financial backers. As part of its latest fundraise, the venture firm raised $2.6bn for its eighth fund and $1bn to deploy across parallel funds, which will invest in specific sectors, such as certain diagnostics or therapeutics. Flagship is also likely to raise extra money for its eighth fund later this year, helping it meet a target of $3bn for the investment vehicle. Much of the investments from Flagship’s fund VIII will be focused on platforms that use AI in novel ways to develop drugs, according to Noubar Afeyan, who founded Flagship in 2000. “Each of the pools of capital we raise supports around 25 companies; I wouldn’t be surprised if the majority of [the companies in fund VIII] are but for AI we wouldn’t do them,” said Afeyan. The close of Flagship’s latest raise is a bullish sign for venture investment in biotech, which has been trying to recover following a downturn caused by the end of a pandemic-inspired boom in addition to a series of interest rate hikes. https://on.ft.com/3S0S1DI

Nourish Your Biotech Venture with Strategic Funding In the fast-paced world of biotech innovation, securing the right funding at the right time is not just about fueling growth; it's about unlocking the full potential of your venture. At CellTech Accelerator, we understand the transformative power of strategic funding. Our mission goes beyond mere financial connections; we aim to be the catalyst that propels your startup to unprecedented success. 🚀 Unlocking Potential with Tailored Funding Strategies Our approach to funding is personalized and strategic. We don't just connect you with any funds; we carefully match your startup with the right investors who share your vision and commitment to innovation. This bespoke matchmaking process ensures that the funding you receive is not just capital but a partnership that aligns with your long-term objectives. 🌐 Collaboration with Leading Venture Capitals Our network includes some of the leading venture capital firms in Taiwan and beyond. These are entities known for their keen interest in groundbreaking biotech projects and their ability to support startups through more than just financial investment. They provide valuable mentorship, access to industry networks, and strategic guidance to navigate the complex biotech landscape. 💡 Expertise in Government Grant Applications Navigating the intricacies of government grant applications can be daunting. CellTech's expertise in this area becomes your advantage. We possess a deep understanding of the grant application process in Taiwan, enabling us to guide you in presenting your innovation in the best light. Our support maximizes your chances of securing non-dilutive funding, preserving equity while gaining the financial support necessary for research and development. 🔍 Turning Funding Goals into Achievements Joining CellTech Accelerator means embarking on a journey where your funding goals are transformed into tangible achievements. With our support, biotech startups find not just funding but a pathway to scaling their operations, accelerating their development, and bringing life-changing therapies and technologies to the market sooner. Let's navigate the future of biotech together. With CellTech Accelerator, discover how strategic funding can do more than just propel your venture forward—it can unlock the untapped potential waiting to redefine what's possible in biotechnology. Join us and turn your funding goals into milestones of biotech innovation. #StrategicFunding #BiotechInnovation #CellTechEmpowerment

From biotech innovations to semiconductor developments and fintech enhancements, here's a recap of this week's most noteworthy venture deals: Metsera - $290M, Biotech: Topping the charts, New York-based Metsera came out of stealth mode with a massive $290 million in funding, led by ARCH Venture Partners. Metsera is setting new standards in biopharmaceutical care with its oral and injectable treatment options. Rivos Inc. - $250M, Semiconductor: As generative AI fuels demand for advanced semiconductor solutions, Rivos secured $250 million in a Series A-3 round led by Matrix Capital Management Company, L.P. Ramp - $150M, Fintech: In fintech, New York's Ramp saw its valuation jump to $7.65 billion with a $150 million round led by Khosla Ventures and Founders Fund. The spend management startup continues to impress the market, scaling rapidly since its inception in 2019 with a total of $1.8 billion raised to date. Two Chairs - $72M, Healthcare: San Francisco's Two Chairs raised $72 million to expand its behavioral health services. The funding, a mix of debt and equity, was led by Amplo and Fifth Down Capital, supporting the startup's innovative therapist-patient matching platform. Cape - $61M, Mobile: Addressing privacy concerns in telecommunications, Arlington, Virginia-based Cape launched with a $61 million investment from A* and Andreessen Horowitz. Cape's privacy-first mobile network aims to safeguard user data, marking a significant entry into the telecom industry. Avive Solutions Inc. - $57M, Healthcare: Specializing in medical technology, San Francisco's Avive Solutions raised $56.5 million to enhance its connected defibrillator products. This growth equity round, led by Catalyst Health Group and others, will expand its life-saving technologies. Asher Biotherapeutics - $55M, Biotech: With a $55 million Series C from RA Capital Management, Asher Biotherapeutics continues to develop targeted immunotherapies for critical health conditions, further cementing its position in the biotech industry. Corner Therapeutics - $54M, Biotech: New to the scene, Corner Therapeutics from Watertown, Massachusetts, secured $54 million for its work in immunotherapy, led by Och-Ziff Capital Management, to advance novel treatment options. Kontakt.io - $48M, Artificial Intelligence: Kontakt.io's $47.5 million funding round led by Goldman Sachs Asset Management will boost its healthcare facility analytics services, demonstrating the growing importance of AI in optimizing healthcare operations. Anvilogic - $45M, Cybersecurity: Rounding out the top deals, Anvilogic's $45 million Series C led by Evolution Equity Partners underscores the critical need for enhanced cybersecurity measures amidst rising digital threats. Global Spotlight: This week’s largest international deal saw London-based Skyports Drone Services secure approximately $109 million for its drone delivery service, signaling strong global interest in urban air mobility solutions.

Weekly Column: Italy's Venture Capital Scene Our featured venture capital firm this week is Indaco Venture Partners. Based in Milan, it's a prominent investment firm which supports innovative startups and growth-stage companies. ✔Investment Thesis: Focus on high-tech startups across various sectors (digital, medtech, electronics, robotics, and cleantech). ✔Mission: Financing innovative companies with strong growth potential. ✔Digital: Investing in startups that are developing cutting-edge digital tech and solutions. ✔Medtech: Supporting companies that are innovating in the medical tech space. ✔Electronics and Robotics: Backing startups that are pushing the boundaries in electronics and robotics. ✔Cleantech: Investing in tech that promote sustainability and environmental responsibility. ✔Capital: The firm manages 6 funds, with a total of over €350 million in AUM. ✔Indaco Ventures Fund I: Focus on growth-stage companies whose competitive advantage stems from cutting-edge proprietary technologies and innovations. This fund focuses on: Digital, DeepTech - Electronics, and Medtech - Healthcare primarily in Italy, but also EU, USA, Canada, and Israel. ✔Indaco Bio Fund: Focused on innovative pharmacological therapies, with particular attention to Oncology, CNS, Ophthalmology, Metabolic diseases, Virology, and Infectious diseases primarily in Italy, but also EU, USA, Canada, and Israel. ✔Anchor Institutional Investors: Major institutional investors in Indaco SGR Funds include Intesa Sanpaolo, Fondazione Cariplo, European Investment Fund, CDP Venture Capital SGR, Quaestio SGR, and Inarcassa. ✔Strategic Partnerships: In the digital sector, Indaco has an advisory partnership with growITup-Cariplo Factory; for biotech and pharma, Indaco has a partnership with Università di Milano. ✔Stages: Seed, Early Stage, and Growth Stage investments. ✔Ticket Size: Typically ranging from €500K to €10M. ✔Geography: Italy, EU, USA, Canada, and Israel. ✔Managing Partners: Davide Turco, Antonella Beltrame, Alvise Bonivento, and Elizabeth Robinson. ✔Recent Investments: May 30, 2024: Seed Round - MicThera (€1M) December 12, 2023: Series A - Freya Biosciences ($38M) December 10, 2023: Series A - Hoba Therapeutics (€23M) November 14, 2023: Series C - Nouscom (€67.5M) November 8, 2023: Series C - D-Orbit (€100M) July 26, 2023: Venture Round - Easy Rain (€5.8M) April 17, 2023: Seed Round - Alia Therapeutics ✔Investments: The firm has made 61 investments to date. Their most recent investment was on May 30, 2024, when MicThera raised €1M. ✔Exits: Indaco Venture Partners has had 9 exits. Some notable exits include Genenta Science, Directa Plus, and Energica Motor Company. Founded in 2016, today Indaco Venture Partners is the largest independent Italian venture capital asset management company. They have a strong presence in Italy, with significant investments in cities such as Milan, Rome, and Turin. 👉For more info, visit: Indaco Venture Partners

This week's venture capital landscape showcases a vibrant mix of biotech breakthroughs, social media innovations, and cutting-edge technology in energy and healthcare. Let's dive into the noteworthy investments: But before we dive in, a special shoutout to Blackbird with their $800m Canva payday 🙌 What a win for the Australian market! Obsidian Therapeutics - $161M, Biotech: Leading the charge in biotech, Obsidian Therapeutics secures a whopping $160.5 million in Series C financing. With Wellington Management at the helm of new investors, Obsidian is pushing the envelope with its engineered cell and gene therapies aimed at cancer treatment. Flip - $144M, Social Media: Flip, a pioneering social commerce platform, captures $144 million, soaring past a $1 billion valuation. Streamlined Ventures led the round, with a notable $50 million from AppLovin. Alterome Therapeutics, Inc Therapeutics - $132M, Biotech: Alterome Therapeutics announces a significant $132 million Series B round, led by Goldman Sachs Alternatives. Diagonal Therapeutics - $128M, Biotech: Another biotech standout, Diagonal Therapeutics emerges with a $128 million Series A. Co-led by BVF PARTNERS, L.P Partners and Atlas Venture. Aerospike - $109M, Database: Aerospike secures a $109 million investment, led by Sumeru Equity Partners, to fuel the demand for scalable databases driven by AI adoption. Alsym Energy - $78M, Energy: Alsym Energy, innovators of nonflammable rechargeable batteries, announces a $78 million round, co-led by Tata Limited and General Catalyst. SiMa.ai - $70M, Semiconductor: Semiconductor startup SiMa.ai raises $70 million in a round led by Maverick Capital, highlighting the critical role of semiconductors in today's tech-driven world. Torus - $67M, Energy: Torus, a pioneer in energy storage and management, secures $67 million in a comprehensive funding round led by Origin Ventures. binx health - $65M, Healthcare: Binx Health, revolutionizing diagnostic testing for sexually transmitted diseases, raises $65 million in Series F funding. Led by Hildred Capital with participation from EQT Life Sciences. Homebase - $60M, Human Resources: Homebase, a comprehensive HR and team management app, locks in $60 million in Series D funding led by L Catterton Growth. . Global Highlights: Stepping outside the U.S., Pigment, a French startup specializing in business forecasting, raised a notable $145 million, marking it as one of the week's largest rounds globally.

Opening Moves: 2024's First Closed Deals Revealed 👇 1. UrbanStems, a US-based company specializing in floral delivery services, recently closed a successful Series C funding round, raising an impressive $5.00 M. This achievement was made possible thanks to the support of SWaN & Legend Venture Partners. 2. Hailing from Thailand and operating in the biotechnology sector, UniFAHS secured $1.40 million in funding for its seed round. The funding was provided by ADB Ventures, InnoSpace (Thailand), and A2D Ventures, reflecting growing interest in the biotech industry. 3. OnCusp Therapeutics raised a substantial $100.00 M in its Series A round. The backing came from a consortium of leading investors, including OrbiMed, Novo Holdings, F-Prime Capital, Marshall Wace, Blackbird Ventures, BioTrack Capital, Catalio Capital Management, and Forge Partners Life Science Partners. 4. An AI company Perplexity secured $73.60 M in Series B funding. The investment was made possible thanks to the support of several prominent venture firms, including New Enterprise Associates (NEA), Bezos Expeditions, Kindred Ventures, Factorial Funds, and Databricks Ventures. 5. Full-Life Technologies a Chinese biotech company raised an impressive $47.30 M in its Series B round. The funding was provided by Chengwei Capital, Sky9 Capital, HongShan, Summer Capital, and Prosperity7 Ventures, showcasing the growing interest in biotech innovations in China. 6. Another Chinese company Silicon made waves by securing a substantial $112.92 M in funding from Phoenix Tree Investment Capital Co., Ltd. and Hengxu Capital. 7. Aso based in China, ATAPEX raised $28.23 M in its Series B, thanks to the backing of Shenzhen Capital Group Co., Ltd and New Value Capital. 8. South Korean software company Mainline secured $20.81 M in funding for its Pre-IPO stage. The investment was provided by InterVest Co., LTD, Kolon Investment Pvt. Ltd., and Hyundai Investments Co., Ltd. 9. Mobilint, Inc., a tech company, secured $15.41 M in its Series B. The funding was sourced from Korea Development Bank, InterVest, KDB Capital Corp., L&S Ventures, Union Investment Partners, Daesung Private Equity, and Game Changer Investment. 10. In the burgeoning field of Artificial Intelligence, ALIGO AI raised $150.00 K in seed funding. Seoul Technology Holdings played a pivotal role in supporting this AI company's early-stage growth. Stay updated for next week's update! DealPotential data is sourced from reliable channels and financial institutions and further ensured its accuracy. #dealpotentialweeklydealradar #investments #privateequity #dealpotential #venturecapital #fundraising #investmentstrategy #marketreport #privatemarket #BusinessNews #funding #innovation #financialnews

Biotech startups often require substantial initial capital to support extensive research and development (R&D), clinical trials, and regulatory approvals before generating any revenue. This high-risk, high-reward environment makes navigating the biotech startup funding landscape particularly complex. This article provides a comprehensive guide to the various funding options available to biotech startups. https://lnkd.in/gmyiP3yx #navigating #biotech #startup #complex #funding #raisingcapital #options

An insightful article by Labiotech.eu on the challenging journey to funding a biotech venture. It's not just about securing funds but also the value investors can bring. The right mix of dilutive and non-dilutive funding sources is crucial, involving governmental grants, subsidies, VC investments, Corporate VC investments, partnerships, collaborations, and the IPO. The latter is not discussed in this article. Hope to see more on that soon. It's time! 👍👊 #Biotech #Lifesciences #Ecosystembuilding #Startup #ScaleUp #Growth #Funding

The venture capital sector is experiencing a surge of investments in technology and healthcare, reflecting the strong innovation across these fields. Here are the major deals making waves right now: - MMI - Maritime and Mercantile International, the Florida-based pioneer in medical robotics, has successfully closed a $110 million Series C funding round, led by Fidelity Investments. - Clumio, known for its innovative cloud data backup and recovery solutions, has raised a robust $75 million in Series D funding, led by Sutter Hill Ventures, with Index Ventures and Altimeter also participating. - Simetrik, a B2B fintech startup from Columbia, secures a $55 million growth equity investment from Goldman Sachs Asset Management, showcasing the growing interest in fintech innovations. - In the radar sensor manufacturing space, Austin's Uhnder, Inc. has raised a $50 million Series D, led by ACME Capital, highlighting the industry's rapid advancement and investor confidence. - Oula, a New York-based maternity care clinic, brings a new approach to maternal healthcare with a $28 million Series B co-led by Revolution Venture Capital and Maverick Ventures, with GV (Google Ventures) participating. - AZmed, based in Paris, is revolutionizing radiology with AI, closing a €15 million Series A from investors including Maison Worms, Techstars, and Teampact.ventures. - Isomab Ltd a UK innovator developing treatments for peripheral arterial disease, secures a £7.5 million seed investment led by Broadview Ventures Inc. - Tagomics, another UK-based company, raises £6.7 million led by Calculus Capital for its disease insight and diagnosis platform. - spektr, the Copenhagen-based compliance startup, received €5 million from Northzone, Seedcamp, and PreSeed Ventures, indicating a growing focus on regulatory tech.

𝐇𝐨𝐰 𝐝𝐨𝐞𝐬 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐟𝐮𝐧𝐝𝐢𝐧𝐠 𝐰𝐨𝐫𝐤? 𝐏𝐚𝐫𝐭 𝐃𝐞𝐮𝐱 Biotech companies, like other startups, typically go through several funding rounds as they grow and develop. Each round serves a specific purpose in the company’s lifecycle and comes with different investor expectations. Here's an overview of the typical funding rounds a biotech company might go through.   𝗣𝗿𝗲-𝗦𝗲𝗲𝗱 𝗙𝘂𝗻𝗱𝗶𝗻𝗴: Pre-seed funding is often used to develop the initial idea, conduct preliminary research, and cover the basic operational costs of starting the company. Sources: Sources funding is usually funded by the founders, close family and friends, or early-stage angel investors. 𝗦𝗲𝗲𝗱 𝗙𝘂𝗻𝗱𝗶𝗻𝗴: Seed funding is the 1st official funding stage and is typically used support early development, including further research, proof-of-concept studies, hiring the first employees, and developing prototypes or early-stage products. Sources: Angel investors, early-stage venture capital (VC) firms, or crowdfunding platforms. Seed funding rounds typically raise $500k-$2 million. 𝗦𝗲𝗿𝗶𝗲𝘀 𝗔 𝗙𝘂𝗻𝗱𝗶𝗻𝗴: Series A funding is used to scale the company's operations, expand R&D, and possibly begin early clinical trials. This round focuses on optimizing the business model, moving to commercialisation and product development. Sources: Venture capital firms typically lead Series A rounds, with investments from institutional investors or strategic partners. Typically, Series A rounds raise approx. $2 million to $15 million.   𝗦𝗲𝗿𝗶𝗲𝘀 𝗕 𝗙𝘂𝗻𝗱𝗶𝗻𝗴: Series B funding is aimed at scaling the business further, including expanding the team, advancing clinical trials, increasing production capabilities, and preparing for commercialization. Sources: More prominent VC firms, private equity investors, and sometimes strategic partners or large corporations. Typically, Series B rounds raise approx. $10 million to $60 million. 𝗦𝗲𝗿𝗶𝗲𝘀 𝗖 𝗮𝗻𝗱 𝗕𝗲𝘆𝗼𝗻𝗱 (𝗦𝗲𝗿𝗶𝗲𝘀 𝗗, 𝗘, 𝗲𝘁𝗰.): These later-stage rounds are typically used for large-scale expansion, including finalizing clinical trials, securing regulatory approvals, expanding marketing and sales efforts, and possibly preparing for an IPO or acquisition. Sources: Late-stage VC firms, private equity funds, hedge funds, and sometimes crossover investors (who invest in both public and private markets). These rounds look to raise around the $100+ million.    𝗜𝗻𝗶𝘁𝗶𝗮𝗹 𝗣𝘂𝗯𝗹𝗶𝗰 𝗢𝗳𝗳𝗲𝗿𝗶𝗻𝗴 (𝗜𝗣𝗢): An IPO is when a company goes public, selling shares to institutional and retail investors on a stock exchange. This provides a significant influx of capital, which can be used to fund further development, expand operations, and pay off early investors. Sources: Public investors through stock exchanges.